<DOC>
	<DOCNO>NCT01216995</DOCNO>
	<brief_summary>Double blind , prospective , randomize , placebo-controlled Safety Efficacy trial ADRCs deliver via intracoronary route treatment patient ST-elevation acute myocardial infarction ( STEMI ) .</brief_summary>
	<brief_title>Safety Efficacy Adipose Derived Regenerative Cells ( ADRCs ) Delivered Via Intracoronary Route Treatment Patients With ST-elevation Acute Myocardial Infarction ( AMI )</brief_title>
	<detailed_description>This prospective , randomize , two arm , placebo-controlled , double blind , study enroll approximately 216 patient thirty-five ( 35 ) international clinical site . Additional blinding measure take assessment study outcome . The dose test material ( ADRCs ) describe protocol . The study include two arm .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Key STsegment Elevation Myocardial Infarction ( STEMI ) Criteria : Ischemic symptom AND ECG : Development pathologic Q wave ECG ; ECG change indicative severe ischemia ( ST segment elevation and/or depression ) ; New leave bundle branch block ; AND Creatine Phosphokinase Isoenzyme ( MB Form ) &gt; 100 IU/L , troponin &gt; 5x upper limit normal admission randomization Successful revascularization culprit lesion major epicardial vessel Key More 24 hour PCI start liposuction Prior myocardial infarction , cardiomyopathy , history congestive heart failure Pacemaker , ICD , contraindication MRI Patients increase bleed risk Cardiogenic shock present postindex PCI</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Heart Attack</keyword>
	<keyword>Regenerative Cells</keyword>
	<keyword>Stem Cells</keyword>
</DOC>